Poseida Therapeutics Reports Disappointing Q4 Results with Missed Revenue and EPS
[vc_row][vc_column][vc_column_text]Poseida Therapeutics, a biotechnology company focused on developing gene therapies for cancer and other genetic diseases, reported disappointing Q4 2022 results on Thursday. The company\’s Q4 GAAP earnings per share (EPS) came in at -$0.39, missing expectations by $0.56. Meanwhile, revenue for the quarter was $10.05 million, down 67.8% year-over-year and missing estimates by $21.7 […]
Poseida Therapeutics Reports Disappointing Q4 Results with Missed Revenue and EPS Read More »